
    
      The Foldax Polymer Aortic Valve is indicated as a replacement for a diseased, damaged, or
      malfunctioning native aortic heart valve via open heart surgery. This is a first in human
      study conducted under US FDA's Early Feasibility Investigational Device Exemption and will
      enroll up to 40 patients. These patients will be followed up to 5 years after implantation.
    
  